Three Ebola vaccines in development amid growing outbreak fears
Three new Ebola vaccines are under development to combat a growing outbreak of the Bundibugyo species, which has killed nearly 250 people and infected over 1,000 suspected cases in the Democratic Republic of Congo, with nine confirmed cases in neighboring Uganda. The International Aids Vaccine Initiative (IAVI), the University of Oxford, and Moderna are all working on these vaccines, with funding provided by the Coalition for Epidemic Preparedness Innovations.

Briefing Summary
AI-generatedThree new Ebola vaccines are under development to combat a growing outbreak of the Bundibugyo species, which has killed nearly 250 people and infected over 1,000 suspected cases in the Democratic Republic of Congo, with nine confirmed cases in neighboring Uganda. The International Aids Vaccine Initiative (IAVI), the University of Oxford, and Moderna are all working on these vaccines, with funding provided by the Coalition for Epidemic Preparedness Innovations. Experts express concern that this outbreak could rival or exceed the severity of the 2014-16 West Africa epidemic. The urgency is underscored by the fact that the outbreak was detected after spreading in a conflict zone with limited healthcare.
Article analysis
Model · rule-basedKey claims
5 extractedMSF stated the situation is 'deeply alarming' and has never before seen 'so many cases' recorded so soon.
The University of Oxford and Moderna are researching vaccines against the Bundibugyo species of Ebola.
IAVI believes this outbreak is threatening to be as severe as, or worse than, the 2014-16 West Africa outbreak.
The outbreak has already killed nearly 250 people and has over 1,000 suspected cases in DR Congo.
Three new vaccines are being developed to tackle the rare species of Ebola.